A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS).
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2013
At a glance
- Drugs Fulvestrant (Primary) ; Tamoxifen
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 23 Jun 2009 Planned initiation date (Jan 2007), actual end date (Jun 2008) and planned number of patients (100) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2008 The expected completion date for this trial is now 1 Jan 2009.